BridgeBio Pharma Debt to Equity Ratio 2018-2024 | BBIO

Current and historical debt to equity ratio values for BridgeBio Pharma (BBIO) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. BridgeBio Pharma debt/equity for the three months ending September 30, 2024 was 0.00.
BridgeBio Pharma Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2024-09-30 $1.88B $-1.22B -1.55
2024-06-30 $1.88B $-1.08B -1.73
2024-03-31 $1.89B $-1.04B -1.82
2023-12-31 $1.89B $-1.34B -1.41
2023-09-30 $1.85B $-1.20B -1.55
2023-06-30 $1.85B $-1.35B -1.37
2023-03-31 $1.84B $-1.21B -1.52
2022-12-31 $1.87B $-1.24B -1.50
2022-09-30 $1.86B $-1.13B -1.65
2022-06-30 $1.88B $-1.01B -1.85
2022-03-31 $1.85B $-1.04B -1.78
2021-12-31 $1.88B $-0.87B -2.17
2021-09-30 $1.52B $-0.74B -2.06
2021-06-30 $1.54B $-0.46B -3.36
2021-03-31 $1.48B $-0.39B -3.81
2020-12-31 $0.60B $0.11B 5.62
2020-09-30 $0.57B $0.22B 2.65
2020-06-30 $0.58B $0.33B 1.78
2020-03-31 $0.54B $0.45B 1.20
2019-12-31 $0.16B $0.47B 0.33
2019-09-30 $0.12B $0.52B 0.23
2019-06-30 $0.00B $0.00B 0.00
2019-03-31 $0.00B $0.00B 0.00
2018-12-31 $0.00B 0.00
2018-09-30 $0.00B $0.00B 0.00
2017-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.426B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00